Medicare Drug Cost Savings: What the Inflation Reduction Act Means for You in 2027

If you take prescription medications and you’re on Medicare, the Inflation Reduction Act (IRA) has brought real changes to what you pay. Since 2022, this federal law has rolled out a series of benefits that lower out-of-pocket costs for Medicare beneficiaries — and in 2027, those protections continue to expand.

Here’s what you need to know about how the IRA affects your prescription drug costs this year.

What Is the Inflation Reduction Act?

The Inflation Reduction Act was signed into law in August 2022. It made several significant changes to how Medicare covers prescription drugs — changes that phase in over multiple years. The goal: make medications more affordable and predictable for people on Medicare.

Key provisions include:

• A $35 monthly cap on insulin
• Free vaccines recommended by ACIP
• A hard cap on annual out-of-pocket Part D spending
• Medicare’s ability to negotiate drug prices
• Penalties for drug companies that raise prices faster than inflation

These aren’t proposals — they’re law. And most of them are already in effect.

The $35 Insulin Cap

If you use insulin, this is one of the most immediate changes you may have already noticed. Under the IRA, your cost for a 30-day supply of covered insulin is capped at $35 — whether you get it through Medicare Part B (typically administered in a doctor’s office or through a traditional pump) or Part D (your prescription drug plan).

Before the IRA, insulin costs could range from $45 to over $1,000 per month depending on the type and your coverage. The $35 cap has made a measurable difference for people who depend on insulin to manage diabetes.

Important note: The $35 cap applies to the cost share for covered insulins only. If you use a brand-name insulin that isn’t on your plan’s formulary, or if you’re paying for supplies not covered by your plan, you may still have additional costs. Always check with your plan or pharmacist to understand what’s covered.

$0 Copay on ACIP-Recommended Vaccines

Starting in 2023, all vaccines recommended by the Advisory Committee on Immunization Practices (ACIP) are covered at no cost under Medicare Part D. That means you pay $0 copay — no deductible, no coinsurance — for vaccines like:

• Shingles (Shingrix)
• Pneumococcal (pneumonia)
• Hepatitis B
• Tetanus, diphtheria, and pertussis (Tdap)
• And others recommended by ACIP

This is a straightforward benefit. If you’re enrolled in a Part D plan (stand-alone or integrated with a Medicare Advantage plan), you can get ACIP-recommended vaccines at any network pharmacy with no out-of-pocket cost.

If you’re eligible for both Medicare and Medicaid, or if you receive Extra Help, you may have had access to free vaccines before the IRA. But for the majority of Medicare beneficiaries, the IRA extended this benefit to everyone.

The Annual Out-of-Pocket Cap: $2,400 in 2027

Perhaps the most significant long-term change is the annual out-of-pocket (OOP) cap on Part D prescription drug costs.

Before 2025, there was no hard limit on what you could spend on covered Part D drugs. Once you passed the catastrophic coverage phase, you continued to pay 5% of the cost — with no ceiling. For people with expensive medications, that could mean thousands of dollars in annual costs.

The IRA changed that:

• 2025: $2,000 annual OOP cap
• 2026: $2,100 (indexed for inflation)
• 2027: $2,400 (indexed for inflation)

Once you hit the cap, you pay $0 for covered Part D medications for the rest of the calendar year. This is a hard stop — no exceptions for specialty drugs or tier-based cost sharing.

The cap also includes a Medicare Prescription Payment Plan option that lets you spread your out-of-pocket costs into monthly payments throughout the year, rather than paying large amounts at the pharmacy counter.

What the cap covers: Deductibles, copayments, and coinsurance for drugs covered under your Part D plan. Drugs you pay for that aren’t on your plan’s formulary do not count toward the cap.

Medicare Drug Price Negotiation

One of the biggest structural changes in the IRA is that Medicare can now negotiate prices directly with drug manufacturers. Before the IRA, Medicare was prohibited from negotiating drug prices — a restriction that didn’t apply to other federal programs like the VA.

Starting in 2026, Medicare began negotiating prices for the 10 highest-spending drugs. That number is expected to expand over time. The negotiated prices are confidential, but the intent is to bring down the cost of medications that Medicare spends the most on.

For beneficiaries, the impact of negotiated prices should show up as lower costs for those specific drugs at the pharmacy. However, it’s important to understand that negotiated prices apply to a limited number of medications, not the entire formulary.

Inflation Penalties on Drug Price Hikes

Another IRA provision targets drug companies that raise prices faster than inflation. Starting in 2023, if a manufacturer raises a drug’s price faster than the rate of inflation, they must pay a rebate to Medicare.

For certain drugs, your cost share is limited to 20% of the inflation-adjusted price increase. This means:

• If a drug company raises a price from $100 to $150, but inflation only supports a $125 increase, your cost share would be based on the $125 amount — not the full $150
• The manufacturer pays the difference as a rebate to Medicare

This provision doesn’t directly lower your out-of-pocket cost at the pharmacy counter the way the $35 insulin cap does. But it creates a financial disincentive for drug companies to raise prices faster than inflation, which helps keep overall drug spending in check.

What This Means for You

The IRA’s impact on Medicare drug costs is real and ongoing. Here’s a quick summary of where things stand in 2027:

• Insulin: $35/month cap on covered insulins (Part B and Part D)
• Vaccines: $0 copay for ACIP-recommended vaccines under Part D
• Annual OOP cap: $2,400 on covered Part D drug costs
• Drug price negotiation: Medicare negotiating prices for high-spending drugs
• Inflation penalties: Manufacturers paying rebates for above-inflation price hikes

These changes apply to everyone enrolled in Medicare Part D or a Medicare Advantage plan with drug coverage. They don’t require you to do anything — they’re automatic benefits built into your coverage.

If you have questions about how these changes affect your specific medications or plan, a licensed agent at Trek Insurance Solutions can help you review your options.

---

Trek Insurance Solutions is a Third-Party Marketing Organization (TPMO). We do not offer every plan available in your area. Any information we provide is limited to those plans we do offer in your area. Please contact Medicare.gov or 1-800-MEDICARE to get information on all of your options.

888-960-0442 · trekis.net